Q1 2025 LifeMD Inc Earnings Call Transcript
Key Points
- LifeMD Inc (LFMD) reported a 70% year-over-year growth in core telehealth revenue, driven by strong performance in weight management and new offerings like men's hormone therapy.
- The company achieved a significant improvement in telehealth adjusted EBITDA, reaching $5.3 million from a loss of $1.3 million in the same period last year.
- LifeMD Inc (LFMD) expanded its Medicare initiative, now covering over 21 million Medicare Part B beneficiaries across 26 states, with plans to reach 49 states by the end of Q2.
- The company launched strategic collaborations with LillyDirect and NovoCare to improve access to GLP-1 medications for weight management patients, enhancing its competitive position in virtual obesity care.
- LifeMD Inc (LFMD) achieved its first quarter with positive GAAP net income, reporting $608,000 or $0.01 per diluted share, compared to a net loss in the previous year.
- Gross margin for the first quarter declined by 270 basis points year-over-year due to changes in revenue and pharmacy mix.
- The number of WorkSimpli active subscribers declined by 5%, although the segment continued to perform well financially.
- LifeMD Inc (LFMD) faces challenges in integrating cash pay and insurance-sponsored offerings, increasing the complexity of their programs.
- The company has not yet finalized the pricing structure for care provided alongside new weight management therapies, which could impact future revenue.
- LifeMD Inc (LFMD) anticipates potential seasonal softness in certain segments, such as RexMD's sexual health offerings, which may affect sequential growth.
Good afternoon. Thank you for joining us today to discuss LifeMD's results for the first quarter ended March 31, 2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session.
Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected.
These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, May 6, 2025.
'The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Also, please note that management will be discussing certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
